Scleroderma Lung Fibrosis and Biologic DrugsPaola Caramaschi*, Domenico Biasi, Sara Pieropan, Cinzia Scambi and Silvano Adami
Rheumatology Unit, Department of Medicine, University of Verona, Italy
- *Corresponding Author:
- Paola Caramaschi
Unità di Reumatologia
P.le Scuro, 37134 Verona, Italy
Tel: 0039 45 8124049
Fax: 0039 45 8126881
E-mail: [email protected]
Received Date: October 24, 2011; Accepted Date: November 23, 2011; Published Date: November 25, 2011
Citation: Caramaschi P, Biasi D, Pieropan S, Scambi C, Adami S (2011) Scleroderma Lung Fibrosis and Biologic Drugs. Rheumatology S1:001. doi: 10.4172/2161-1149.S1-001
Copyright: © 2011 Caramaschi P, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Biologic agents have revolutionized the management of some inflammatory diseases like rheumatoid arthritis, seronegative spondyloarthropathies and Crohn’s disease; the selective inhibition of mediators involved in systemic chronic processes have allowed to expand the knowledge among the complex pathogenic pathways that are involved in inflammation and damage. The off-label use of biologic drugs is expanding.
This review highlights the theoretical basis that may support the use of biologic drugs in the treatment of Systemic Sclerosis (SSc), a disabling and sometimes devastating disease whose treatment remains largely unsatisfactory. Some progresses have been made concerning the vascular complications of the disease, but the skin and visceral fibrosis, which is the hallmark of the disease, is still orphan of effective therapy. Moreover the results of the limited clinical experience about biologic agent administration in SSc and SSc-interstitial lung disease are presented.